Products AC220
AC220 Phase 1 Completed 💤 Quiet Relapsed AML, Refractory AML
Feb 1, 2016 → Nov 13, 2018
About AC220 AC220 is a phase 1 stage product being developed by Daiichi Sankyo for Relapsed AML. The current trial status is completed. This product is registered under clinical trial identifier NCT02675478. Target conditions include Relapsed AML, Refractory AML.
Clinical Trials (4) NCT ID Phase Status Start Completion Indication NCT02675478 Phase 1 Completed Feb 1, 2016 Nov 13, 2018 Relapsed AML NCT01565668 Phase 2 Completed Apr 1, 2012 Mar 1, 2015 Leukemia, Myeloid, Acute NCT01468467 Phase 1 Completed Apr 1, 2012 Mar 1, 2015 Leukemia, Myeloid, Acute NCT00462761 Phase 1 Completed Jan 1, 2007 Dec 1, 2009 Acute Myeloid Leukemia
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3 Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab Eli Lilly Phase 1/2
Other Products from Daiichi Sankyo